Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Signing of Definitive Agreement to Acquire Drug Lab 118 (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Grace Therapeutics, Inc GRCE

Healthcare
Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel... see more

Recent & Breaking News (NDAQ:GRCE)

Acasti Pharma Announces Preliminary Topline Results Met All Primary Outcome Measures in the Single Dose Pharmacokinetic Study for GTX-101, the Company's Drug Candidate for the Treatment of Postherpetic Neuralgia (PHN)

GlobeNewswire December 22, 2022

Acasti Pharma Reports Second Quarter 2023 Operational Results

GlobeNewswire November 14, 2022

Acasti Pharma to Present at Q4 Investor Summit

GlobeNewswire November 9, 2022

Acasti Pharma to Report Second Quarter 2023 Financial Results on Monday, November 14, 2022

GlobeNewswire November 7, 2022

Acasti Announces Court Dismissal of Stockholder Litigation

GlobeNewswire September 30, 2022

Acasti Announces Voting Results from 2022 Annual and Special Meeting of Shareholders

GlobeNewswire September 29, 2022

Acasti Pharma Inc. Discusses Clinical Progress of Lead Assets and 2022 Catalysts with The Stock Day Podcast

Newsfile September 21, 2022

Acasti Pharma to Participate in the Lytham Partners Fall 2022 Investor Conference

GlobeNewswire September 14, 2022

Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-102, the Company's Drug Candidate for the Treatment of Ataxia Telangiectasia

GlobeNewswire September 13, 2022

Acasti Pharma to Participate at the H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 12, 2022

Acasti Pharma Reports First Quarter 2023 Operational Results

GlobeNewswire August 11, 2022

Acasti Pharma to Report First Quarter 2023 Financial Results on Thursday, August 11, 2022

GlobeNewswire August 2, 2022

Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-101, the Company's Drug Candidate for the Treatment of Postherpetic Neuralgia

GlobeNewswire July 27, 2022

Acasti Pharma Inc. Discusses Year-End Results and Clinical Development Progress with The Stock Day Podcast

Newsfile July 7, 2022

Acasti Pharma Announces Annual Grants of Performance Stock Options

GlobeNewswire June 22, 2022

Acasti Pharma Reports Fiscal Year 2022 Operational Results

GlobeNewswire June 21, 2022

Acasti Pharma Schedules Fiscal Year 2022 Business Update Conference Call

GlobeNewswire June 16, 2022

Acasti Pharma Announces the Issuance of Additional Patents for GTX-104 and GTX-101

GlobeNewswire June 14, 2022

Acasti Pharma Inc. Retains Lytham Partners to Lead Strategic Investor Relations and Shareholder Communication Program

PR Newswire May 23, 2022

Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting All Endpoints

GlobeNewswire May 18, 2022